Research on Economic Evaluation of Rare Diseases

亚洲社会药学

Research on Economic Evaluation of Rare Diseases

Li Tongtong, Zhang Fang*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

出版日期:2017-06-20 发布日期:2017-08-31

Research on Economic Evaluation of Rare Diseases

Li Tongtong, Zhang Fang*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

Online:2017-06-20 Published:2017-08-31
Contact: Zhang Fang, associate professor. Major research area: health economic policy evaluation and pharmacoeconomics. Tel: 024-43520327, E-mail: xzhangf@126.com.

摘要/Abstract

摘要： Objective To study the related literatures on rare diseases and to provide references for economic evaluation of rare diseases. Methods Related literatures on rare diseases which were published in the Springer, Web of Science, China National Knowledge Infrastructure, Wan Fang Database and VIP Database from January 2006 to September 2016 were retrieved. Results and Conclusion A total of 101 articles were searched out and after screening, 53 articles were used for the analysis. Four aspects were classified for the research，including cost-effectiveness, economic evaluation, budget analysis and socioeconomic impact of rare diseases. In the field of rare diseases research, cost-effectiveness and rare economic evaluation were the research hotpots. The number of budget analysis and socioeconomic impact research was few. Therefore, researchers should have a comprehensive study on various aspects of rare diseases research so that they can provide references for rare diseases policy making in different countries.

关键词: rare diseases, orphan drugs, economic, cost

Abstract: Objective To study the related literatures on rare diseases and to provide references for economic evaluation of rare diseases. Methods Related literatures on rare diseases which were published in the Springer, Web of Science, China National Knowledge Infrastructure, Wan Fang Database and VIP Database from January 2006 to September 2016 were retrieved. Results and Conclusion A total of 101 articles were searched out and after screening, 53 articles were used for the analysis. Four aspects were classified for the research，including cost-effectiveness, economic evaluation, budget analysis and socioeconomic impact of rare diseases. In the field of rare diseases research, cost-effectiveness and rare economic evaluation were the research hotpots. The number of budget analysis and socioeconomic impact research was few. Therefore, researchers should have a comprehensive study on various aspects of rare diseases research so that they can provide references for rare diseases policy making in different countries.

Key words: rare diseases, orphan drugs, economic, cost

Li Tongtong, Zhang Fang. Research on Economic Evaluation of Rare Diseases [J]. 亚洲社会药学.

Li Tongtong, Zhang Fang. Research on Economic Evaluation of Rare Diseases [J]. Asina Journal Of Social Pharmacy.

[1]	Li Meng, Huang Zhe. Empirical Analysis on Performance Evaluation of A Pharmaceutical Company Based on Economic Value Added[J]. 亚洲社会药学, 2021, 16(2): 154-162.
[2]	Gu Pu, Wei Tingting, Wu Zhi’ang. Research on Marketing Strategies of Product D — a Chronic Myelogenous Leukemia Drug for Pharmaceutical Company A[J]. 亚洲社会药学, 2020, 15(3): 153-158.
[3]	Wang Wanting, Xing Hua. Application Research of Earned Value Management in New Drug Research and Development Projects[J]. 亚洲社会药学, 2020, 15(1): 16-21.
[4]	Wang Yanqi, Chen Binbin, Zhao Mengmeng, Sun Lihua. Pharmacoeconomic Evaluation of Rituximab (Hanlikang) for Patients with Rheumatoid Arthritis[J]. 亚洲社会药学, 2020, 15(1): 22-29.
[5]	Duan Xiaomin, Lu Yan, Sun Lihua. Research on Acquiring Data for Pharmacoeconomic Evaluation[J]. 亚洲社会药学, 2016, 11(4): 155-157.
[6]	Lu Yan, Ren Xiaoxiao, Jia Yaozhu, Sun Lihua. Medical Insurance Data in China from Pharmacoeconomic Evaluation Perspective: Problems and Countermeasures[J]. 亚洲社会药学, 2016, 11(4): 158-162.
[7]	Lu Yan, Duan Xiaomin, Ren Xiaoxiao, Sun Lihua. Accumulation and Utilization Status of Medicare Data in Taiwan from the Perspective of Pharmacoeconomic Evaluation[J]. 亚洲社会药学, 2016, 11(3): 107-111.
[8]	Duan Xiaomin, Lu Yan, Sun Lihua. Impact of Big Medical Data on Medical Record Data Formation Model from Pharmacoeconomic Evaluation Perspectives[J]. 亚洲社会药学, 2016, 11(3): 112-115.
[9]	SUN Shu-jun;WU Zhi-ang. An Analysis of Doctors’ Incentive Mechanismin Grass-root Medical Organizations[J]. , 2015, 10(2): 82-85.
[10]	ZHANG Hao;WU Zhi-ang. The Cost-Benefit Analysis of Government Supervisionof Post-Market Drug Risks[J]. , 2015, 10(2): 57-60.
[11]	LIU Ming;SUN Li-hua. Family Economic Risk Caused by Five Major ChronicDiseases among Urban Residents: A Comparative StudyBased on the Data from 9 Cities in China[J]. , 2014, 9(4): 187-192.
[12]	DONG Hong-yan;SUN Li-hua. Three Therapeutic Regimens in Treatment of Community-acquiredPneumonia: A Cost-effectiveness Analysis[J]. , 2014, 9(4): 193-196.
[13]	DU Li-zhe;SUN Li-hua. Countermeasures to Reduce Economic Burden of the Schizophrenia in China[J]. , 2014, 9(2): 83-86.
[14]	ZHANG Lei;XING Hua;WU Yang. Study on the Pharmaceutical E-commerce B to C Modelfrom Perspective of Transaction Costs[J]. , 2014, 9(2): 92-95.

亚洲社会药学

Research on Economic Evaluation of Rare Diseases

Research on Economic Evaluation of Rare Diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价